1. Home
  2. BRNX vs ONCO Comparison

BRNX vs ONCO Comparison

Compare BRNX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrenX Ltd. Ordinary Shares

BRNX

BrenX Ltd. Ordinary Shares

N/A

Current Price

$1.06

Market Cap

3.5M

Sector

N/A

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.54

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRNX
ONCO
Founded
2012
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
BRNX
ONCO
Price
$1.06
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
107.7K
★ 6.4M
Earning Date
09-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
$35,081.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.00
$0.09
52 Week High
$10.36
$798.00

Technical Indicators

Market Signals
Indicator
BRNX
ONCO
Relative Strength Index (RSI) 31.29 37.94
Support Level N/A $0.09
Resistance Level $2.49 $1.02
Average True Range (ATR) 0.17 0.10
MACD -0.07 -0.02
Stochastic Oscillator 15.09 1.39

Price Performance

Historical Comparison
BRNX
ONCO

About BRNX BrenX Ltd. Ordinary Shares

BrenX Ltd is reshaping industrial energy to make it cleaner, more reliable, and lower cost. Building on its proprietary bGen thermal energy storage technology, which converts electricity and recovered heat into dispatchable energy, BrenX develops, owns, operates, and optimizes energy assets that serve industrial customers and data centers. From local generation and storage to grid connectivity and intelligent energy management, BrenX brings together technologies and infrastructure to create complete energy platforms around customer needs, with flexible energy assets designed to meet growing energy demand.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: